Assessment of the biodistribution and metabolism of 5-fluorouracil as monitored by 18F PET and 19F MRI: A comparative animal study

Nuclear Medicine and Biology

Volumn 23, Issue 7, 1996, Pages 897-906

  Brix, Gunnar ^a   Bellemann, Matthias E ^a   Haberkorn, Uwe ^a   Gerlach, Ludwig ^a   Lorenz, Walter J ^a  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

5 Fluorouracil; Chemotherapy; Experimental neoplasms; Magnetic resonance imaging; Positron emission tomography

Indexed keywords

FLUORINE 18; FLUOROURACIL;

ANIMAL EXPERIMENT; ARTICLE; CANCER GRAFT; CONTROLLED STUDY; DRUG DISTRIBUTION; DRUG METABOLISM; NUCLEAR MAGNETIC RESONANCE; PHARMACOKINETICS; POSITRON EMISSION TOMOGRAPHY; RAT;

ANIMALS; FLUORINE RADIOISOTOPES; FLUOROURACIL; LIVER; LIVER NEOPLASMS, EXPERIMENTAL; MAGNETIC RESONANCE IMAGING; MALE; MUSCLE, SKELETAL; RATS; RATS, INBRED ACI; RATS, INBRED BUF; TISSUE DISTRIBUTION; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 0030271612     PISSN: 09698051     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0969-8051(96)00122-9     Document Type: Article

References (46)

1. 18F PET imaging of the cytostatic agent 5-fluorouracil. IEEE Trans. Nucl. Sci. 41, 2856-2861.
2. 18F]fluorouracil in liver tumors. In: Radioactive Isotopes in Clinical Medicine and Research (Edited by Bergmann H. and Sinzinger H.), pp. 79-84-Birkhäuser-Verlag, Basel, Boston, Berlin.
3. 19F MR imaging of 5-fluorouracil and α-fluoro-β-alanine, Magn. Reson. Imaging 11, 1193-1201.
4. 19F MR imaging. Magn. Reson. Med. 34, 302-307.
5. 5. Collins J. M. and Dedrick R. L. (1982) Pharmacokinetics of anticancer drugs. In: Pharmacologic Principles of Cancer Treatment (Edited by Chabner B. A.), pp. 77-99. Saunders, Philadelphia.
6. 6. Collins J. M., Dedrick R. L., King F. G., Speyer J. L. and Myers C. E. (1980) Nonlinear pharmacokinetic models for 5-fluorouracil in man: Intravenous and intraperitoneal routes. Clin. Pharmacol. Ther. 28, 235-246.
7. 7. Dimitrakopoulou A., Strauss L. G., Clorius J. H., Ostertag H., Schlag P., Heim M., Oberdorfer F., Helus F., Haberkorn U. and van Kaick G. (1993) Studies with positron emission tomography after systemic adminstration of fluorine-18-uracil in patients with liver metastases from colorectal cancer. J. Nucl. Med. 34, 1075-1081.
8. 8. Doll J., Brix, G., Bellemann M. E., Ostertag H. J., Trojan H., Haberkorn U., Schmidlin P. and Lorenz W. J. (1995) Improvement of spatial resolution in PET by implementing scanner characteristics in iterative image reconstruction algorithms. In: Medical Physics (Edited by Richter J.), pp. 322-323. Linea Plus Druck GmbH, Frankfurt.
9. 19F nuclear magnetic resonance spectroscopy. Cancer Res. 51, 5806-5812.
10. 10. Fishman A. J., Rubin R. H. and Strauss H. W. (1994) In vivo imaging in drug discovery and design. In: Pharmacokinetics of Drugs (Edited by Welling P. G. and Balant L. P.), pp. 481-503. Springer-Verlag, Berlin, Heidelberg, New York.
11. 19F magnetic resonance spectroscopy. Br. J. Radiol. 63, 547-553.
12. 12. Heidelberger C. H., Chaudhuri N. K., Danneberg P., Mooren D., Griesbach L., Duschinsky R., Schnitzer R. J., Pleven E. and Scheiner J. (1957) Fluorinated pyrimidines, a new class of tumour-inhibitory compounds. Nature 179, 663-666.
13. 13. Heidelberger C (1981) On the rational development of a new drug: The example of the fluorinated pyrimidines. Cancer Treat. Rep. 65, 3-9.
14. 14. Hoffman E. J. and Phelps M. E. (1986) Positron emission tomography: Principles and Quantitation. In: Positron Emission Tomography and Autoradiography: Principles and Applications for the Brain and Heart (Edited by Phelps M. E., Mazziotta J. and Schelbert H.), pp. 237-286. Raven Press, New York.
15. 18F]uracil positron emission tomography (PET). Eur. J. Cancer 29A, 1682-1686.
16. 16. Hoverath H., Kübler W. K., Ostertag H. J., Doll J., Ziegler S. I., Knopp M. V. and Lorenz W. J. (1993) Scatter correction in the transaxial slices of a whole-body positron emission tomograph. Phys. Med. Biol. 38, 717-728.
17. 19F nuclear magnetic resonance spectroscopy, for patients receiving chemotherapy with or without methotrexate pretreatment. Cancer Res. 48, 1680-1688.
18. 18. Kemeny N. (1983) The systemic chemotherapy of hepatic metastases. Semin. Oncol. 10, 138-158.
19. 19. Lewitt R. M. and Muehllehner G. (1986) Accelerated iterative reconstruction for positron emission tomography based on the EM algorithm for maximum likelihood estimation. IEEE Trans. Med. Imag. 5, 16-22.
20. 20. Lowitz B. B. and Casciato D. A. (1983) Cancer chemotherapeutic agents. In: Manual of Clinical Oncology (Edited by Casciato D. A. and Lowitz B. B.), pp. 25-49. Little, Brown, Boston.
21. 21. Malet-Martino M. C., Martino R., Lopez A., Béteille J. P., Bon M., Bernadou J. and Armand J. P. (1984) New approach to metabolism of 5′-deoxy-5-fluorouridine in humans with fluorine-19 NMR. Cancer Chemother. Pharmacol. 13, 31-35.
22. 22. Maziére B. and Delforge J. (1994) Contribution of positron emission tomography to pharmacokinetic studies. In: Pharmacokinetics of Drugs (Edited by Welling P. G. and Balant L. P.), pp. 455-480. Springer-Verlag, Berlin, Heidelberg, New York.
23. 19F MRS studies of fluoropyrimidine chemotherapy. A review. NMR Biomed. 2, 133-141.
24. 19F NMR spectroscopy. NMR Biomed. 4, 274-278.
25. 25. Mezrich R. (1995) A perspective on K-space. Radiology 195, 297-315.
26. 26. Morris H. P. (1965) Studies on the development, biochemistry and biology of experimental hepatomas. Adv. Cancer Res. 9, 227-302.
27. 27. Myers C. E. (1981) The pharmacology of the fluoropyrimidines. Pharmacol. Rev. 33, 1-15.
28. 18F-labeled 5-fluorouracil of very high purity. J. Lab. Comps. Radiopharm. 27, 137-145.
29. 29. Ostertag H., Kübler W. K., Doll J. and Lorenz W. J. (1989) Measured attenuation correction methods. Eur. J. Nucl. Med. 15, 722-726.
30. 30. Pinedo H. and Peters G. F. (1988) Fluorouracil: Biochemistry and pharmacology. J. Clin. Oncol. 6, 1653-1664.
31. 31. Port R. E., Bachert P. and Semmler W. (1991) Kinetic modeling of in vivo nuclear magnetic resonance spectroscopy data: 5-Fluorouracil in liver and liver tumors. Clin. Pharmacol. Ther. 49, 497-505.
32. 19F nuclear magnetic resonance spectroscopy pharmacokinetics. J. Clin. Oncol. 8, 1868-1873.
33. 19F NMR spectroscopoy of the antimetabolite 5-fluorouracil and its analogues: An assessment of drug metabolism. Biochem. Pharmacol. 39, 857-863.
34. 34. Ritschel W. A. (1992) Handbook of Basic Pharmacokinetics, 4th edn. Drug Intelligence Publications, Hamilton, Illinois.
35. 19F NMR study during 5-FU chemotherapy in patients with metastases of colorectal adencarcinoma. Magn. Reson. Imaging. 12, 497-511.
36. 36. Semmler W., Bachert-Baumann P., Gückel F., Ermark F., Schlag P., Lorenz W. J. and van Kaick G. (1990) Real-time follow-up of 5-fluorouracil metabolism in the liver of tumor patients by means of F-19 MR spectroscopy. Radiology 174, 141-145.
37. 37. Shepp L. A. and Vardi Y. (1982) Maximum likelihood reconstruction for emission tomography. IEEE Trans. Med. Imag. 1, 113-122.
38. 19F magnetic resonance spectroscopy studies of the metabolism of 5-fluorouracil in murine RIF-1 tumors and liver. Cancer Res. 51, 1384-1390.
39. 39. Sijens P. E., Baldwin N. J. and Ng T. C. (1991) Multinuclear MR investigations of the metabolic response of the murine RIF-1 tumor to 5-fluorouracil chemotherapy. Magn. Reson. Med. 19, 373-385.
40. 40. Sotos G. A., Grogan L. and Allegra C. J. (1994) Preclinical and clinical aspects of biomodulation of 5-fluorouracil. Cancer Treat. Rev. 20, 11-49.
41. 19F NMR. Br. J. Cancer 50, 113-117.
42. 42. Strauss L. G. and Conti P. S. (1991) The application of PET in clinical oncology. J. Nucl. Med. 32, 623-648.
43. 43. Tilsley D. W. O., Harte R. J. A., Jones T., Brady F., Luthra S. K., Brown G. and Price P. M. (1993) New techniques in the pharmacokinetic analysis of cancer drugs: IV. Positron emission tomography. Cancer Surv. 17, 425-442.
44. 18F]-5-fluorouracil in mice: Effects of route of administration, strain, tumour and dose. Cancer Chemother. Pharmacol. 26, 205-209.
45. 45. Wolf W., Albright M. J., Silver M. S., Weber H., Reichardt U. and Sauer R. (1987) Fluorine-19 NMR spectroscopic studies of the metabolism of 5-fluorouracil in the liver of patients undergoing chemotherapy. Magn. Reson. Imaging 5, 165-169.
46. 19F NMR spectroscopic pharmacokinetics in tumor-bearing humans and rabbits. Proc. Natl. Acad. Sci. USA 87, 492-496.